Alterations in the MAPK (mitogen-activated protein kinase) pathway are typical for these tumors, with mutations in the BRAF gene being most common.16 Because of the rarity of PXA, no formal treatment guidelines have yet been established. The gene discussed is BRAF; the disease is pleomorphic xanthoastrocytoma.